Optimization of Dose Selection for Non-Vitamin K Antagonist Oral Anticoagulants
The era of oral anticoagulation dawned in the 1940s, when the first clinical trials of the drug that would become known as warfarin were conducted [1,2]. The introduction of warfarin into practice in the 1950s revolutionized the care of patients with or at risk for thromboembolism [3]. In the ensuing decades, warfarin therapy was shown to be effective for reducing the risk of a variety of thromboembolic disorders, including stroke and thromboembolism associated with atrial fibrillation (AF) [4]. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 30, 2017 Category: Cardiology Authors: James E. Tisdale Source Type: research
Editorial Board
(Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 29, 2017 Category: Cardiology Source Type: research
Editorial Commentary: Where do we stand after DANISH? It ’s tough to make predictions, especially about the future
This famous quote by Yogi Berra highlights the longstanding quest amongst cardiologists to be able to accurately predict which patients with cardiomyopathy are most likely to benefit from an implantable cardioverter defibrillator (ICD). As we are currently in the 4th decade of the ICD era, there still remains uncertainty regarding the most effective application of ICD, particularly, in patients with nonischemic cardiomyopathy (NICM). (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 28, 2017 Category: Cardiology Authors: Raul D. Mitrani, Jeffrey J. Goldberger Source Type: research
Editorial commentary: Where do we stand after DANISH? Its tough to make predictions, especially about the future
This famous quote by Yogi Berra highlights the longstanding quest amongst cardiologists to be able to accurately predict which patients with cardiomyopathy are most likely to benefit from an implantable cardioverter defibrillator (ICD). As we are currently in the 4th decade of the ICD era, there still remains uncertainty regarding the most effective application of ICD, particularly, in patients with nonischemic cardiomyopathy (NICM). (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 28, 2017 Category: Cardiology Authors: Raul D. Mitrani, Jeffrey J. Goldberger Source Type: research
Where do we stand after DANISH? Its tough to make predictions, especially about the future
This famous quote by Yogi Berra highlights the longstanding quest amongst cardiologists to be able to accurately predict which patients with cardiomyopathy are most likely to benefit from an implantable cardioverter defibrillator (ICD). As we are currently in the 4th decade of the ICD era, there still remains uncertainty regarding the most effective application of ICD, particularly, in patients with nonischemic cardiomyopathy (NICM). (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 28, 2017 Category: Cardiology Authors: Raul D. Mitrani, Jeffrey J. Goldberger Source Type: research
Ed Board
(Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 23, 2017 Category: Cardiology Source Type: research
Table of Contents
(Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 23, 2017 Category: Cardiology Source Type: research
Tissue-engineered vascular grafts for congenital cardiac disease: Clinical experience and current status
Congenital heart disease is a leading cause of death in the newborn period, and man-made grafts currently used for reconstruction are associated with multiple complications. Tissue engineering can provide an alternative source of vascular tissue in congenital cardiac surgery. Clinical trials have been successful overall, but the most frequent complication is graft stenosis. Recent studies in animal models have indicated the important role of the recipient ׳s immune response in neotissue formation, and that modulating the immune response can reduce the incidence of stenosis. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 21, 2017 Category: Cardiology Authors: Joseph D. Drews, Hideki Miyachi, Toshiharu Shinoka Source Type: research
Tissue Engineered Vascular Grafts for Congenital Cardiac Disease: Clinical Experience and Current Status
Congenital heart disease is a leading cause of death in the newborn period, and man-made grafts currently used for reconstruction are associated with multiple complications. Tissue engineering can provide an alternative source of vascular tissue in congenital cardiac surgery. Clinical trials have been successful overall, but the most frequent complication is graft stenosis. Recent studies in animal models have indicated the important role of the recipient's immune response in neotissue formation, and that modulating the immune response can reduce the incidence of stenosis. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 21, 2017 Category: Cardiology Authors: Joseph D. Drews, Hideki Miyachi, Toshiharu Shinoka Source Type: research
Editorial commentary: Deconstructing the dogma: Its time to untangle and reassess acute myocardial infarction care
Since first being described clinically over a century ago, the care and outcomes for acute myocardial infarction (AMI) have improved greatly [1]. For the first half of the 20th century, the care for myocardial infarction was driven by biological plausibility of treatment strategies [1], including an emphasis on reducing myocardial oxygen consumption with complete bedrest, increasing myocardial oxygen supply with supplemental oxygen, and sublingual nitroglycerin for coronary vasodilation, as well as symptom relief with intravenous morphine with the intention to limit physical and emotional excursion [1]. (Source: Trends in ...
Source: Trends in Cardiovascular Medicine - June 20, 2017 Category: Cardiology Authors: Rohan Khera, Dharam J. Kumbhani Source Type: research
Editorial commentary: Indications for catheter ablation of ventricular tachycardia in the modern era
The types of patients with structural heart disease (SHD) undergoing catheter ablation for ventricular tachycardia (VT) have changed dramatically over the past 20 years. In the past, most patients undergoing ablation had coronary artery disease (CAD) and presented with recurrent, slow, hemodynamically stable VT remote after a large transmural myocardial infarction (MI). As ablation techniques, mapping systems, therapies for advanced heart failure (HF), and experience have improved, more patients undergoing ablation for VT have hemodynamically unstable VTs commonly of multiple morphologies causing multiple implantable defib...
Source: Trends in Cardiovascular Medicine - June 20, 2017 Category: Cardiology Authors: Basil Saour, Bradley P. Knight Source Type: research
Deconstructing the Dogma: It's Time to Untangle and Reassess Acute Myocardial Infarction Care
Since first being described clinically over a century ago, the care and outcomes for acute myocardial infarction (AMI) have improved greatly [1]. For the first half of the 20th century, the care for myocardial infarction was driven by biological plausibility of treatment strategies [1], including an emphasis on reducing myocardial oxygen consumption with complete bedrest, increasing myocardial oxygen supply with supplemental oxygen and sublingual nitroglycerin for coronary vasodilation, as well as symptom relief with intravenous morphine with the intention to limit physical and emotional excursion [1]. (Source: Trends in C...
Source: Trends in Cardiovascular Medicine - June 20, 2017 Category: Cardiology Authors: Rohan Khera, Dharam J. Kumbhani Source Type: research
Indications for Catheter Ablation of Ventricular Tachycardia in the Modern Era
The types of patients with structural heart disease (SHD) undergoing catheter ablation for ventricular tachycardia (VT) have changed dramatically over the past twenty years. In the past, most patients undergoing ablation had coronary artery disease (CAD) and presented with recurrent, slow, hemodynamically stable VT remote after a large transmural myocardial infarction (MI). As ablation techniques, mapping systems, therapies for advanced heart failure (HF) and experience have improved, more patients undergoing ablation for VT have hemodynamically unstable VTs commonly of multiple morphologies causing multiple implantable de...
Source: Trends in Cardiovascular Medicine - June 20, 2017 Category: Cardiology Authors: Basil Saour, Bradley P. Knight Source Type: research
Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation
The development of nonvitamin K antagonist oral anticoagulants (NOACs) has been a major advance in therapy for patients requiring oral anticoagulation, particularly for long-term indications such as stroke prevention in atrial fibrillation (AF). The NOACs are generally easier to dose and manage due to less heterogeneity of effect across individuals and fewer drug and food interactions, compared with warfarin. However, the treatment effect of NOACs may vary based on important patient characteristics, particularly renal function. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 19, 2017 Category: Cardiology Authors: Benjamin A. Steinberg, Jeffrey B. Washam Source Type: research
Appropriate dosing of non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation
The development of non-Vitamin K antagonist oral anticoagulants (NOACs) has been a major advance in therapy for patients requiring oral anticoagulation, particularly for long-term indications such as stroke prevention in atrial fibrillation (AF). The NOACs are generally easier to dose and manage due to less heterogeneity of effect across individuals and fewer drug and food interactions, compared with warfarin. However, the treatment effect of NOACs may vary based on important patient characteristics, particularly renal function. (Source: Trends in Cardiovascular Medicine)
Source: Trends in Cardiovascular Medicine - June 19, 2017 Category: Cardiology Authors: Benjamin A. Steinberg, Jeffrey B. Washam Source Type: research
